JPMorgan raised the firm’s price target on Insmed (INSM) to $111 from $90 and keeps an Overweight rating on the shares. After meeting with management, the firm believes Insmed is on a “strong trajectory.” It expects an on-time brensocatib approval in August.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM: